1. Market Research
  2. > Biotechnology Market Trends
  3. > Biotechnology Analysis & Statistics in the United States, July 2019

Biotechnology Analysis & Statistics in the United States, July 2019

Customer Support

Talk to Veronica

+1 718 514 2762

Publishers

  • All
    • La Merie Publishing

All regions

data types

1-16 of 16 reports

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

  • $ 2700
  • Industry report
  • June 2019

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysisThis report provides you with a landscape description and analysis of T-cell and natural kille ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Pharmaceutical
  • Countries : United States
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends

  • $ 2451
  • Industry report
  • May 2018

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & dealsT-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive T-cell ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

  • $ 2622
  • Industry report
  • January 2018

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trendsIt is estimated that ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : Australia, United States
The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

  • $ 2451
  • Industry report
  • January 2017

The Oncolytic Virus Landscape 2017: an analysis of pipeline,stakeholders, deals, industry trends & opportunitiesThe field of oncolytic viruses wasquite dormant in the first decade of the 2000s, characterized ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

  • $ 912
  • Industry report
  • December 2016

Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates ...

  • Industries : Therapy
  • Countries : United States
BCMA-Targeted Antibodies & T-Cells in: October 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

BCMA-Targeted Antibodies & T-Cells in: October 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

  • $ 228
  • Industry report
  • November 2016

BCMA-Targeted Antibodies & T-Cells in: October 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells This pdf report contains information about TCR & CAR engineered T-cells and NK cells ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

  • $ 798
  • Industry report
  • November 2016

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States
Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates

Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates

  • $ 228
  • Industry report
  • November 2016

Anti-CD22 Immunotherapeutics in:October 2016 R&D and Business Tracker for Antibody-Drug Conjugates This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

  • $ 228
  • Industry report
  • October 2016

CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells This pdf report contains information about TCR & CAR engineered T-cells and NK cells ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies

CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies

  • $ 228
  • Industry report
  • October 2016

CD123-Targeted Immunotherapeutics in:September 2016 R&D and Business Tracker for Bispecific AntibodiesThis pdf report contains information about Bispecific Antibodies released during the month of Septembe ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

  • $ 570
  • Industry report
  • August 2016

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
CD123: a paradigmatic target for immunotherapeutic treatment modalities

CD123: a paradigmatic target for immunotherapeutic treatment modalities

  • $ 798
  • Industry report
  • August 2016

CD123: a paradigmatic target for immunotherapeutic treatment modalities This report describes and evaluates the competitive landscape of CD123-targeted immunotherapeutics based on different treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

  • $ 1083
  • Industry report
  • February 2016

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but „difficult-to-drug“ ...

  • Industries : Medical Biotechnology, Pharmaceutical, Pathology
  • Countries : United States
Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update

  • $ 456
  • Industry report
  • February 2016

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 UpdateThe Competitive Intelligence Report „Anti-VEGF/R Biosimilars and Biosuperiors ...

  • Industries : Oncology, Therapy, Medical Biotechnology
  • Countries : United States
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis

Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis

  • $ 2679
  • Industry report
  • November 2015

Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis This report describes and analyzes the situation of antibody-drug conjugates as ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

  • $ 456
  • Industry report
  • July 2015

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor AnalysisThe Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States



Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on